Sort   by:  
 Page size 
UnknownPopulation Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Not available
S-EPMC4879370 | biostudies-literature
UnknownComparative bioavailability of single-dose zavegepant during and between migraine attacks: A phase 1, randomized, open-label, fixed-sequence, two-period study.
Not available
S-EPMC11884223 | biostudies-literature
UnknownPopulation Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
Not available
S-EPMC5986681 | biostudies-literature
UnknownEffects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Not available
S-EPMC3157302 | biostudies-literature
UnknownPopulation Pharmacokinetic Modeling of the Oral Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in Adults.
Not available
S-EPMC12358308 | biostudies-literature
UnknownMass balance and pharmacokinetic characterization of zavegepant in healthy male subjects.
Not available
S-EPMC11441388 | biostudies-literature
UnknownA phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine.
Not available
S-EPMC12849519 | biostudies-literature
UnknownAnisotropic deformation response of single protein molecules.
Not available
S-EPMC1568916 | biostudies-literature
UnknownCharacterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam.
Not available
S-EPMC11794968 | biostudies-literature
UnknownWhole body vibration training during allogeneic hematopoietic cell transplantation-the effects on patients' physical capacity.
Not available
S-EPMC7060160 | biostudies-literature
Sort   by:  
 Page size